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Abstract 
A microfluidic system for rapid and quantitative detection of plasma biomarkers from patients at intensive care units is 
presented. The system integrates a magnetic bead based immunoassay onto a microfluidic disposable chip. Biomarker 
concentrations down to 10 pg/mL were detected within 40 minutes with the presented system. Chemiluminescence is used as 
detection method, which enables signal readout with a lens-less photodiode as optical detection unit. Due to the combination of an 
efficient detection system and simple chip fabrication, our system fulfills the requirements for a potential point-of-care device: cost 
efficiency, speed, and high sensitivity. 
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1. Introduction 
 
Every year, millions of people decease from sepsis worldwide. Triggered by an infection, sepsis is caused by an 
overwhelming response of the body’s immune system, and is a very critical medical condition. Sepsis is the major 
challenge at the intensive care units today. About 36% of all patients with sepsis do not survive, even after  
_______ 
 
* Corresponding author. Tel.: +43(0) 50550-4462; fax: +43(0)50550-4450. 
E-mail address: helene.zirath.fl@ait.ac.a  
© 2014 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Peer-review under responsibility of the scientific committee of Eurosensors 2014
497 H. Zirath et al. /  Procedia Engineering  87 ( 2014 )  496 – 499 
professional treatment [1]. The most efficient treatment of sepsis can be performed when it is detected at an early 
stage. A method for early detection of sepsis is the accurate observation of specific biomarkers, which enables fast 
therapeutic intervention [2, 3]. This strategy is referred to immune monitoring. The conventional methods for immune 
monitoring are performed in centralized labs and require typically 4 hours between blood sample and result. These 
methods can only be conducted by trained laboratory staff and require expensive equipment. We address this need for 
a rapid device with a cost effective microfluidic system for the fast and quantitative detection of sepsis biomarkers 
within 40 minutes. Our aim is to enable decentralized immune monitoring with multiple measurements per day directly 
at the intensive care unit.  
 
2. Approach 
2.1 Microfluidic chip and measurement setup 
 
As reporting principle, chemiluminescent enzyme linked immunosorbent assays (ELISAs) are used for analysis, 
performed with magnetic beads as solid support. The chip material is polymethyl methacrylate - acrylonitrile butadiene 
styrene (PMMA-ABS) with milled microfluidic channels and a 20 μL reaction chamber. In Fig. 1a, a photograph of 
the 20x3 mm disc-shaped microfluidic chip inside the lower part of the measurement container is shown, filled with 
magnetic beads. The elliptical shape of the reaction chamber reduces dead volumes and thus provides efficient 
washing of the beads between the incubation steps. A meander-shaped mixing structure is integrated in the chip for 
an efficient mixing of the two-component chemiluminescent substrate. The bottom of the reaction chamber is 
structured to facilitate air-bubble-free loading [4] and the chip is bonded with an adhesive transparent film. During the 
fluidic protocol, the chip is enclosed in a chip holder with integrated needle-connected tubings, which are perforating 
the adhesive film (see Fig. 1b). The reagents and wash buffer are introduced in the chip by pressure driven flow. A 
PDMS layer between the chip and the holder guarantees an airproof interface. During washing and introduction of 
reagents, the magnetic beads are captured with a permanent magnet. A vibrating element is used for the dispersion of 
beads in the reaction chamber during incubation.  
 
2.2 Microfluidic on-chip ELISA  
 
The magnetic beads are pre-coated with capture antibodies corresponding to the biomarker analyte. Before the 
on-chip ELISA is performed, the chip is loaded with magnetic beads. As a first step in the ELISA, 20 μL plasma 
spiked with the biomarker of interest is introduced into the reaction chamber through the plasma inlet. During filling, 
the magnetic beads are captured with a permanent magnet. Before each incubation step, the magnetic beads are 
distributed through the chamber by activating a vibrating element. In this manner, the whole volume in the reaction 
chamber is utilised, and it prohibits the beads to form clusters. After a 3 min incubation, the reaction chamber and 
beads are washed three times with washing buffer (PBS, 0,1 % Triton-X-100) through the main inlet of the chip. In 
the next step, the biotinylated detection antibody is introduced and incubated for 3 minutes, and thereafter followed 
by 3 washing sequences. In the third incubation step, also lasting for 3 minutes, streptavidin-conjugated horseradish 
peroxidase (SA-HRP) is covalently bound to the biotin on the detection antibody. After the last 3 washing steps, the 
two-component chemiluminescent substrate is mixed on chip within the meander channel. After the mixed substrate 
has entered the reaction chamber, the magnetic beads are distributed in the chamber, and the reaction between HRP 
and the substrate is activated. The enzyme horseradish peroxidase catalyses the oxidation of the substrate, and thereby 
light is emitted. During the chemiluminescent signal detection, the chip is incased in a light-tight container including 
a silicon photodiode. The intensity of the measured signal correlates with a specific concentration of biomarker in the 
plasma. The readout unit allows a low-noise and highly sensitive detection of light with standard photodiodes. In Fig. 
1c, the upper part of the measurement container with the integrated photodiode is depicted. A schematic overview of 
the magnetic beads ELISA is seen in Fig. 2a, and in Fig. 2b the measurement container is illustrated.  
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Fig. 1. (a) Photograph of the 20x3 mm disc-shaped microfluidic chip inside the lower part of the measurement container, filled with magnetic 
beads. MS: mixing structure; RC: reaction chamber; CS1: inlet for chemiluminescent substrate 1; CS2: inlet for chemiluminescent substrate 2; IN: 
the main inlet, used for wash buffer (WB), detection-antibody (DAB) and enzyme (SA-HRP); OUT: outlet; PL: inlet for plasma. (b) Cross section 
of the fluidic set-up. During the fluidic protocol, the microfluidic chip is interfaced via a chip holder with integrated needle ports, sealing layer and 
alignment pillars. After the fluidic protocol, the chip is transferred to the measurement container for signal detection. (c) Upper part of the 
measurement container with the integrated photodiode (PD).  
 
 
Fig. 2 (a) Chemiluminescent magnetic beads ELISAs are used as method for biomarker analysis. The magnetic beads are pre-coated with capture 
antibodies before introduced into the microfluidic reaction chamber. During the ELISA protocol, the magnetic beads are incubated with biomarker 
spiked plasma, biotinylated detection antibody and SA-HRP, each with an incubation time of three minutes. (b) Schematic drawing of the cross 
section of the microfluidic ELISA chip in the measurement container with an integrated silicon photodiode for detection of the chemiluminescent 
signal. 
3. Results and discussion 
In order to establish an on-chip protocol for the biomarker ELISA, the different parameters were first optimized 
by performing off-chip ELISAs. The sensitivity and specificity obtained by a standard ELISA had to be retained when 
reducing the incubation times and volumes of the magnetic beads ELISA.  A microplate reader was used for the 
chemiluminescent detection (EnSpire, PerkinElmer). Before proceeding with the ELISA on-chip, the protocol was 
further established for measuring the signal with the developed read out unit and photodiode.   
3.1 On-chip ELISA 
 
With the developed microfluidic chip and readout unit, magnetic beads ELISAs have been performed for detection 
of the biomarker IL-8. Concentrations between 10 pg/mL and 1000 pg/mL could be detected, which is the same 
dynamic range as when performing a standard ELISA. In addition, the concentrations are corresponding to the clinical 
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relevant values. In Fig. 3a and b, standard curves obtained when performing the established magnetic beads ELISA 
off-chip and on-chip are shown. For both systems, 3 min incubation times and 20 μL per reaction was used, and the 
signals were measured with the photodiode. The on-chip standard curve has a high correlation with the off-chip curve. 
In future work the microfluidic system will be used for on-chip ELISAs for detection of the biomarkers IL-10, IL-6 
and TNF-α. All biomarkers are essential for monitoring of sepsis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Chemiluminescent signal when measuring different concentrations of IL-8 spiked in 10 % plasma. (a) Magnetic beads ELISA performed 
off-chip and measured with a silicon photodiode. IL-8 could be detected between 10 pg/mL to 1000 pg/mL. (b) Magnetic beads ELISA performed 
with the developed microfluidic chip. Also on-chip, IL-8 could be detected between 10 pg/mL to 1000 pg/mL.  (RLU= Relative Luminescence 
Units).  
4. Conclusions 
With the developed system, concentrations of the biomarker IL-8 spiked in plasma can be measured between 10 
pg/mL to 1000 pg/mL. These concentrations are in the range of conventional ELISAs and correspond to clinical 
meaningful values. Furthermore, each incubation step requires 3 minutes, which result in a total analysis time of less 
than 40 min. The usage of cost effective photodiodes as light detectors instead of photomultipliers does not reduce the 
sensitivity or dynamic range. With chemiluminescence as detection method the light emission can be measured 
immediately after adding the fluidic substrate. Due to simple chip fabrication and a cost efficient detection system, 
our approach shows promising features for the development into a point-of-care diagnostic device. Our contribution 
is a significant step towards an automated system for the rapid detection of plasma biomarkers in disposable cartridges 
for immune monitoring at intensive care units.  
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